{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:43:40Z","timestamp":1791845020905,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Charit\u00e9"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with cancer often believe dietary supplements (DS) such as micronutrients and botanical products to be health supporting and non-toxic despite growing concerns regarding potential pharmacological interactions. Studies on the prevalence of DS use among patients with cancer are heterogeneous and mainly conducted at university-based cancer centers. This survey focused on a particular cancer patient group treated in an ambulatory setting without regular access to professional nutritional counselling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a history of cancer or hematological malignancy were included in this survey. A self-reported questionnaire was used to evaluate the different aspects of DS use, changes in dietary habits and patients\u2019 demographic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Almost every second patient reported using DS (47.2%). Women (56.3%), patients with an academic degree (56.0%) and non-smokers (84.8%) were more inclined to use DS. Along with magnesium (16.6%), calcium (14.3%), multivitamins (12.0%) and vitamin C (9.4%), use of herbal supplements (12.6%) was common. Women (84.8% vs. 74.9% of men,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009\u2009&lt;\u20090.001) and patients younger than 65\u00a0years (84.4% vs. 77.2% of patients\u2009&gt;\u200965 y,\n                      <jats:italic>p<\/jats:italic>\n                      = \u20090.002) sought dietary advice more often. Support of the immune system was the main reason for DS use (26.4%) and a relevant number of patients (49.6%) reported to have changed their dietary habits following cancer diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DS use is common among patients with cancer treated in an ambulatory setting. This finding should encourage oncologists to implement detailed questioning about DS use and dietary habits to prevent potential interactions and offer substantial advice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-021-03594-7","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T15:03:00Z","timestamp":1617721380000},"page":"1917-1925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Dietary supplement use in ambulatory cancer patients: a survey on prevalence, motivation and attitudes"],"prefix":"10.1007","volume":"147","author":[{"given":"Maja","family":"Tank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Franz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-9102","authenticated-orcid":false,"given":"Kristina","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"3594_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12906-016-1372-x","volume":"16","author":"SM Alsanad","year":"2016","unstructured":"Alsanad SM, Howard RL, Williamson EM (2016) An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med 16:393. https:\/\/doi.org\/10.1186\/s12906-016-1372-x","journal-title":"BMC Complement Altern Med"},{"key":"3594_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3945\/jn.110.133025","volume":"141","author":"RL Bailey","year":"2011","unstructured":"Bailey RL et al (2011) Dietary supplement use in the United States, 2003\u20132006. J Nutr 141:261\u2013266. https:\/\/doi.org\/10.3945\/jn.110.133025","journal-title":"J Nutr"},{"key":"3594_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.7150\/jca.13818","volume":"7","author":"R Caccialanza","year":"2016","unstructured":"Caccialanza R et al (2016) Nutritional support in cancer patients: a position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). J Cancer 7:131\u2013135. https:\/\/doi.org\/10.7150\/jca.13818","journal-title":"J Cancer"},{"key":"3594_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1001\/jamaoncol.2015.0388","volume":"1","author":"LG Daenen","year":"2015","unstructured":"Daenen LG et al (2015) Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncol 1:350\u2013358. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0388","journal-title":"JAMA Oncol"},{"key":"3594_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1634\/theoncologist.2012-0223","volume":"17","author":"EL Davis","year":"2012","unstructured":"Davis EL, Oh B, Butow PN, Mullan BA, Clarke S (2012) Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist 17:1475\u20131481. https:\/\/doi.org\/10.1634\/theoncologist.2012-0223","journal-title":"Oncologist"},{"key":"3594_CR6","doi-asserted-by":"publisher","first-page":"e00156","DOI":"10.1002\/prp2.156","volume":"3","author":"J de Jong","year":"2015","unstructured":"de Jong J et al (2015) Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect 3:e00156. https:\/\/doi.org\/10.1002\/prp2.156","journal-title":"Pharmacol Res Perspect"},{"key":"3594_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12906-018-2325-3","volume":"18","author":"L Drozdoff","year":"2018","unstructured":"Drozdoff L, Klein E, Kiechle M, Paepke D (2018) Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med 18:259. https:\/\/doi.org\/10.1186\/s12906-018-2325-3","journal-title":"BMC Complement Altern Med"},{"key":"3594_CR8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/jn\/nxaa040","volume":"150","author":"M Du","year":"2020","unstructured":"Du M et al (2020) Dietary supplement use among adult cancer survivors in the United States. J Nutr 150:1499\u20131508. https:\/\/doi.org\/10.1093\/jn\/nxaa040","journal-title":"J Nutr"},{"key":"3594_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/acm.2008.0387","volume":"15","author":"LM Ferrucci","year":"2009","unstructured":"Ferrucci LM, McCorkle R, Smith T, Stein KD, Cartmel B (2009) Factors related to the use of dietary supplements by cancer survivors. J Altern Complement Med 15:673\u2013680. https:\/\/doi.org\/10.1089\/acm.2008.0387","journal-title":"J Altern Complement Med"},{"key":"3594_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00404-017-4348-2","volume":"295","author":"C Fremd","year":"2017","unstructured":"Fremd C et al (2017) Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Arch Gynecol Obstet 295:1239\u20131245. https:\/\/doi.org\/10.1007\/s00404-017-4348-2","journal-title":"Arch Gynecol Obstet"},{"key":"3594_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1534735412473642","volume":"12","author":"M Frenkel","year":"2013","unstructured":"Frenkel M et al (2013) Integrating dietary supplements into cancer care. Integr Cancer Ther 12:369\u2013384. https:\/\/doi.org\/10.1177\/1534735412473642","journal-title":"Integr Cancer Ther"},{"key":"3594_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ctim.2019.02.016","volume":"43","author":"J Friedman","year":"2019","unstructured":"Friedman J, Birstler J, Love G, Kiefer D (2019) Diagnoses associated with dietary supplement use in a national dataset. Complement Ther Med 43:277\u2013282. https:\/\/doi.org\/10.1016\/j.ctim.2019.02.016","journal-title":"Complement Ther Med"},{"key":"3594_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3322\/caac.21397","volume":"67","author":"H Greenlee","year":"2017","unstructured":"Greenlee H et al (2017) Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 67:194\u2013232. https:\/\/doi.org\/10.3322\/caac.21397","journal-title":"CA Cancer J Clin"},{"key":"3594_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000502945","volume":"27","author":"C Guthlin","year":"2020","unstructured":"Guthlin C et al (2020) KOKON: A Germany-Wide Collaborative Research Project to identify needs, provide information, foster communication and support decision-making about complementary and alternative medicine in oncology. Complement Med Res 27:105\u2013111. https:\/\/doi.org\/10.1159\/000502945","journal-title":"Complement Med Res"},{"key":"3594_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12911-019-0857-1","volume":"19","author":"X He","year":"2019","unstructured":"He X et al (2019) ALOHA: developing an interactive graph-based visualization for dietary supplement knowledge graph through user-centered design. BMC Med Inform Decis Mak 19:150. https:\/\/doi.org\/10.1186\/s12911-019-0857-1","journal-title":"BMC Med Inform Decis Mak"},{"key":"3594_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13063-019-3193-y","volume":"20","author":"SM Helmer","year":"2019","unstructured":"Helmer SM, Rogge AA, Fischer F, Pach D, Horneber M, Roll S, Witt CM (2019) Evaluation of a blended-learning training concept to train oncology physicians to advise their patients about complementary and integrative medicine (KOKON-KTO): study protocol for a prospective, multi-center, cluster-randomized trial. Trials 20:90. https:\/\/doi.org\/10.1186\/s13063-019-3193-y","journal-title":"Trials"},{"key":"3594_CR17","unstructured":"Holzapfel CKA, Jaeckel B, Martignoni M, Hauner D, Hauner H (2020) Ern\u00e4hrungsformen und Einnahme von Nahrungserg\u00e4nzungsmitteln bei Patienten mit Tumorerkrankungen"},{"key":"3594_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1177\/1534735418808597","volume":"17","author":"M Horneber","year":"2018","unstructured":"Horneber M, van Ackeren G, Fischer F, Kappauf H, Birkmann J (2018) Addressing unmet information needs: results of a clinician-led consultation service about complementary and alternative medicine for cancer patients and their relatives. Integr Cancer Ther 17:1172\u20131182. https:\/\/doi.org\/10.1177\/1534735418808597","journal-title":"Integr Cancer Ther"},{"key":"3594_CR19","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1038\/srep06587","volume":"4","author":"YW Hsieh","year":"2014","unstructured":"Hsieh YW, Huang CY, Yang SY, Peng YH, Yu CP, Chao PD, Hou YC (2014) Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies. Sci Rep 4:6587. https:\/\/doi.org\/10.1038\/srep06587","journal-title":"Sci Rep"},{"key":"3594_CR20","first-page":"943","volume":"34","author":"J Huebner","year":"2014","unstructured":"Huebner J et al (2014) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34:943\u2013948","journal-title":"Anticancer Res"},{"key":"3594_CR21","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1038\/s41598-019-41532-3","volume":"9","author":"M Jermini","year":"2019","unstructured":"Jermini M et al (2019) Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Sci Rep 9:5078. https:\/\/doi.org\/10.1038\/s41598-019-41532-3","journal-title":"Sci Rep"},{"key":"3594_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000446008","volume":"39","author":"J Konig","year":"2016","unstructured":"Konig J, Geschwill K, Lang A, Tauchert FK, Hofheinz RD, Kripp M (2016) Use of complementary and alternative medicine in cancer patients: a prospective questionnaire-based study in an oncological outpatient. Clinic Oncol Res Treat 39:260\u2013265. https:\/\/doi.org\/10.1159\/000446008","journal-title":"Clinic Oncol Res Treat"},{"key":"3594_CR23","doi-asserted-by":"publisher","first-page":"e185293","DOI":"10.1001\/jamanetworkopen.2018.5293","volume":"1","author":"AG Levy","year":"2018","unstructured":"Levy AG, Scherer AM, Zikmund-Fisher BJ, Larkin K, Barnes GD, Fagerlin A (2018) Prevalence of and factors associated with patient nondisclosure of medically relevant information to clinicians. JAMA Netw Open 1:e185293. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.5293","journal-title":"JAMA Netw Open"},{"key":"3594_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1017\/S0007114510001728","volume":"104","author":"K Li","year":"2010","unstructured":"Li K, Kaaks R, Linseisen J, Rohrmann S (2010) Consistency of vitamin and\/or mineral supplement use and demographic, lifestyle and health-status predictors: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort. Br J Nutr 104:1058\u20131064. https:\/\/doi.org\/10.1017\/S0007114510001728","journal-title":"Br J Nutr"},{"key":"3594_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1089\/acm.2018.0183","volume":"24","author":"Q Luo","year":"2018","unstructured":"Luo Q, Asher GN (2018) Use of dietary supplements at a comprehensive cancer center. J Altern Complement Med 24:981\u2013987. https:\/\/doi.org\/10.1089\/acm.2018.0183","journal-title":"J Altern Complement Med"},{"key":"3594_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10147-016-1025-6","volume":"22","author":"J Maschke","year":"2017","unstructured":"Maschke J, Kruk U, Kastrati K, Kleeberg J, Buchholz D, Erickson N, Huebner J (2017) Nutritional care of cancer patients: a survey on patients\u2019 needs and medical care in reality. Int J Clin Oncol 22:200\u2013206. https:\/\/doi.org\/10.1007\/s10147-016-1025-6","journal-title":"Int J Clin Oncol"},{"key":"3594_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00228-008-0610-7","volume":"65","author":"G Mazzanti","year":"2009","unstructured":"Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S (2009) Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65:331\u2013341. https:\/\/doi.org\/10.1007\/s00228-008-0610-7","journal-title":"Eur J Clin Pharmacol"},{"key":"3594_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00204-015-1521-x","volume":"89","author":"G Mazzanti","year":"2015","unstructured":"Mazzanti G, Di Sotto A, Vitalone A (2015) Hepatotoxicity of green tea: an update. Arch Toxicol 89:1175\u20131191. https:\/\/doi.org\/10.1007\/s00204-015-1521-x","journal-title":"Arch Toxicol"},{"key":"3594_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1188\/09.ONF.61-68","volume":"36","author":"PE Miller","year":"2009","unstructured":"Miller PE, Vasey JJ, Short PF, Hartman TJ (2009) Dietary supplement use in adult cancer survivors. Oncol Nurs Forum 36:61\u201368. https:\/\/doi.org\/10.1188\/09.ONF.61-68","journal-title":"Oncol Nurs Forum"},{"key":"3594_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/annonc\/mdi110","volume":"16","author":"A Molassiotis","year":"2005","unstructured":"Molassiotis A et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655\u2013663. https:\/\/doi.org\/10.1093\/annonc\/mdi110","journal-title":"Ann Oncol"},{"key":"3594_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000492235","volume":"14","author":"N Schuerger","year":"2019","unstructured":"Schuerger N, Klein E, Hapfelmeier A, Kiechle M, Brambs C, Paepke D (2019) Evaluating the demand for integrative medicine practices in breast and gynecological cancer patients. Breast Care (Basel) 14:35\u201340. https:\/\/doi.org\/10.1159\/000492235","journal-title":"Breast Care (Basel)"},{"key":"3594_CR32","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s00432-017-2509-0","volume":"143","author":"I Shalom-Sharabi","year":"2017","unstructured":"Shalom-Sharabi I, Lavie O, Samuels N, Keinan-Boker L, Lev E, Ben-Arye E (2017) Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting. J Cancer Res Clin Oncol 143:2535\u20132543. https:\/\/doi.org\/10.1007\/s00432-017-2509-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"3594_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1515\/jcim-2013-0048","volume":"11","author":"JM Wilkinson","year":"2014","unstructured":"Wilkinson JM, Stevens MJ (2014) Use of complementary and alternative medical therapies (CAM) by patients attending a regional comprehensive cancer care centre. J Complement Integr Med 11:139\u2013145. https:\/\/doi.org\/10.1515\/jcim-2013-0048","journal-title":"J Complement Integr Med"},{"key":"3594_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00228-019-02700-6","volume":"75","author":"J Ziemann","year":"2019","unstructured":"Ziemann J, Lendeckel A, Muller S, Horneber M, Ritter CA (2019) Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment. Eur J Clin Pharmacol 75:1237\u20131248. https:\/\/doi.org\/10.1007\/s00228-019-02700-6","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03594-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03594-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03594-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T10:11:06Z","timestamp":1622283066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03594-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03594-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All participants gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by the Ethics Committee of the Charit\u00e9 University Hospital, Berlin.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}